Sign in
4

Changes in Ownership

Adaptimmune Therapeutics PLC Filed Acc 0001104659-23-004369

Options or other derivatives

  • Chief Executive Officer acquired 6,488,496 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Rawcliffe Adrian Chief Executive Officer 2023-01-17 Grant or award · Option to purchase Ordinary Shares +4,690,224 4,690,224 D: show line 1 in the form
Rawcliffe Adrian Chief Executive Officer 2023-01-17 Grant or award · Option to purchase Ordinary Shares +1,798,272 1,798,272 D: show line 2 in the form
Loading xslF345X03/tm231655-9_4seq1.xml…